Predicting glucocorticoid resistance in multiple sclerosis relapse via a whole blood transcriptomic analysis.

Predicting GC resistance would allow patients to benefit from prompt initiation of an alternative relapse treatment leading to increased treatment efficacy. Thus, we think our model could contribute to reducing disability development in people with MS.